Author: admin

Epilepsy Pipeline and Clinical Trials Assessment, 2024 Updates: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Novartis AG, Pfizer, Inc., Sanofi SA, Takeda Pharmaceutical

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Epilepsy Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Epilepsy Market.

 

Some of the key takeaways from the Epilepsy Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Epilepsy treatment therapies with a considerable amount of success over the years. 
  • Epilepsy companies working in the treatment market are Receptor Life Sciences, Cerebral Therapeutics, Equilibre Biopharmaceuticals, Cerevel Therapeutics, Elium Therapeutics, CombiGen, Ovid Therapeutics, Otsuka Pharmaceutical Co.,Ltd., SK Biopharmaceuticals, Engrail Therapeutics, Amzell, Xenon Pharmaceuticals Inc., and others, are developing therapies for the Epilepsy treatment 
  • Emerging Epilepsy therapies in the different phases of clinical trials are- RLS103, CT-010, EQU 001, Darigabat, Kv7 Program, CG 01, OV329, OPC-214870, SKL24741, ENX-101, AMZ002, XEN496, and others are expected to have a significant impact on the Epilepsy market in the coming years.   
  • In January 2024, Longboard Pharmaceuticals, a biotechnology company headquartered in the United States, has released encouraging top-line results from the Phase Ib/IIa clinical trial evaluating LP352 (bexicaserin) for the treatment of patients diagnosed with developmental and epileptic encephalopathies (DEEs).
  • In January 2023, Amzell has commenced a randomized, open-label study aimed at assessing the superiority of AMZ002 in treating infantile spasms, a rare form of epilepsy. The primary objective of this study is to compare the efficacy and safety of AMZ002 with Vigabatrin in individuals newly diagnosed with infantile spasms (IS).
  • In March 2022, Lupin has obtained approval from the United States Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for Vigabatrin. This anti-epileptic medication is offered in the form of an oral solution USP (500 mg).
  • In March 2022, The medication Ztalmy, developed by Marinus Pharmaceuticals, has been granted approval by the United States Food and Drug Administration (FDA) for the treatment of seizures in individuals diagnosed with CDKL5 deficiency, a genetic type of epilepsy.

 

Epilepsy Overview

Epilepsy is a neurological disorder characterized by recurrent seizures, which are sudden, uncontrolled electrical disturbances in the brain. These seizures can vary widely in severity and can manifest as convulsions, loss of consciousness, staring spells, or unusual behaviors. Epilepsy can develop at any age and can be caused by various factors, including genetic predisposition, brain injury, infection, or structural abnormalities in the brain.

 

Get a Free Sample PDF Report to know more about Epilepsy Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/epilepsy-pipeline-insight

 

Emerging Epilepsy Drugs Under Different Phases of Clinical Development Include:

  • RLS103: Receptor Life Sciences
  • CT-010: Cerebral Therapeutics
  • EQU 001: Equilibre Biopharmaceuticals
  • Darigabat: Cerevel Therapeutics
  • Kv7 Program: Elium Therapeutics
  • CG 01: CombiGen
  • OV329: Ovid Therapeutics
  • OPC-214870: Otsuka Pharmaceutical Co.,Ltd.
  • SKL24741: SK Biopharmaceuticals
  • ENX-101: Engrail Therapeutics
  • AMZ002: Amzell
  • XEN496: Xenon Pharmaceuticals Inc.

 

Epilepsy Route of Administration

Epilepsy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Epilepsy Molecule Type

Epilepsy Products have been categorized under various Molecule types, such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Epilepsy Pipeline Therapeutics Assessment

  • Epilepsy Assessment by Product Type
  • Epilepsy By Stage and Product Type
  • Epilepsy Assessment by Route of Administration
  • Epilepsy By Stage and Route of Administration
  • Epilepsy Assessment by Molecule Type
  • Epilepsy by Stage and Molecule Type

 

DelveInsight’s Epilepsy Report covers around 90+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Epilepsy product details are provided in the report. Download the Epilepsy pipeline report to learn more about the emerging Epilepsy therapies

 

Some of the key companies in the Epilepsy Therapeutics Market include:

Key companies developing therapies for Epilepsy are – Novartis AG, Pfizer, Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, Abbott Laboratories, GlaxoSmithKline PLC, Johnson & Johnson, Sunovion Pharmaceuticals Inc., UCB S.A., Sun Pharmaceutical, GW Pharmaceuticals plc, H. Lundbeck A/S, Alkem Labs., Eisai Co., and others.

 

Epilepsy Pipeline Analysis:

The Epilepsy pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Epilepsy with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Epilepsy Treatment.
  • Epilepsy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Epilepsy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Epilepsy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Epilepsy drugs and therapies

 

Epilepsy Pipeline Market Drivers

  • Rising awareness and strategic alliance, increasing launch of novel drugs, high burden of epilepsy are some of the important factors that are fueling the Epilepsy Market.

 

Epilepsy Pipeline Market Barriers

  • However, loss of patent protection for branded drugs, high cost of treatment and other factors are creating obstacles in the Epilepsy Market growth.

 

Scope of Epilepsy Pipeline Drug Insight    

  • Coverage: Global
  • Key Epilepsy Companies: Receptor Life Sciences, Cerebral Therapeutics, Equilibre Biopharmaceuticals, Cerevel Therapeutics, Elium Therapeutics, CombiGen, Ovid Therapeutics, Otsuka Pharmaceutical Co.,Ltd., SK Biopharmaceuticals, Engrail Therapeutics, Amzell, Xenon Pharmaceuticals Inc., and others
  • Key Epilepsy Therapies: RLS103, CT-010, EQU 001, Darigabat, Kv7 Program, CG 01, OV329, OPC-214870, SKL24741, ENX-101, AMZ002, XEN496, and others
  • Epilepsy Therapeutic Assessment: Epilepsy current marketed and Epilepsy emerging therapies
  • Epilepsy Market Dynamics: Epilepsy market drivers and Epilepsy market barriers 

 

Request for Sample PDF Report for Epilepsy Pipeline Assessment and clinical trials

 

Table of Contents

1. Epilepsy Report Introduction

2. Epilepsy Executive Summary

3. Epilepsy Overview

4. Epilepsy- Analytical Perspective In-depth Commercial Assessment

5. Epilepsy Pipeline Therapeutics

6. Epilepsy Late Stage Products (Phase II/III)

7. Epilepsy Mid Stage Products (Phase II)

8. Epilepsy Early Stage Products (Phase I)

9. Epilepsy Preclinical Stage Products

10. Epilepsy Therapeutics Assessment

11. Epilepsy Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Epilepsy Key Companies

14. Epilepsy Key Products

15. Epilepsy Unmet Needs

16 . Epilepsy Market Drivers and Barriers

17. Epilepsy Future Perspectives and Conclusion

18. Epilepsy Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Epilepsy Pipeline and Clinical Trials Assessment, 2024 Updates: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Novartis AG, Pfizer, Inc., Sanofi SA, Takeda Pharmaceutical

The Quiet Shift by Dr. Nicole B. Simpson and Sharon Stanford Recognized as a Finalist in International Book Contest

The Quiet Shift: Navigating Through the Emotional and Economic Impact of Aging Parents in the Family is recognized for its outstanding writing, design and overall market appeal out of thousands of books submitted into the Book Excellence Awards.

Reverend Dr. Nicole B. Simpson is a Certified Financial Planner (CFP®) and CEO at Harvest Wealth Financial, a financial investment firm specializing in legacy planning, clergy compensation, and solo practitioner advising. Entering the securities industry in 1991, Nicole has over 30 years of experience in the securities industry and holds Series 7, 63, and 65 Securities licenses.

A compelling speaker, television and radio personality, and author, Dr. Nicole frequently speaks on the lecture circuit and has penned several books on financial and life planning. Her recent release, The Quiet Shift, received numerous international literary awards including a BookFest Award, an International Book Award, a Literary Global Book Award, and Book Excellence Award. She has been named as Investopedia’s Top 100 Advisors for 2023, Investment News Hot 100 and Woman to Watch Trailblazer of the Year Award Finalist. She was also acknowledged with an honorable mention for a lifetime achievement award with Invest in Others. 

A highly sought-after expert, Dr. Nicole has been featured in national and international media publications with appearances on ABC News, CNN News, BBC World News, Huffington Post, Crains NY Business, Fox News, PBS and UPN 9. She is a Board Member of CFP Board Center for Financial Planning Diversity Advisory Group, Chair of the Generation X Community Association, and Provost of the Dare 2 Dream Institute.

Nicole received a Doctorate in Transformational Leadership with top honors from Boston University. Today, she is actively involved in spiritual, emotional and economic empowerment, acting as a teacher, trainer, mentor, and guidance counselor to families and communities across America.

This one-on-one interview shares Dr. Nicole B. Simpson’s background and experience in co-authoring The Quiet Shift Navigating Through the Emotional and Economic Impact of Aging Parents in the Family.

Tell us about The Quiet Shift.

Growing older is a natural part of life. Today people are examining their lives from the perspectives of legacy and posterity and the central theme to both are finances and the emotional capacity to manage them, while preserving healthy family relationships.

The Quiet Shift offers a candid and honest look at the scenarios that life will eventually present to us all, and the solutions and remedies that are available to us to ensure that we find ourselves and those who we love and care for on the winning side of this often-challenging process.

It is through these very real stories that myself and my co-author, Sharon Stanford expound upon, that will help unlock many of the key elements. Together we explore principles necessary to take you from one stage of preparation to the next, and to illuminate proactively what aging and caregiving realistically looks like no matter where you are in this process.

What inspired you to write The Quiet Shift?

As a certified financial planner, my primary focus has been to help people who have endured financial trauma. Financial trauma can cause families to live in poverty for generations. In addition, aging and unexpected illness can deplete all of the savings a family has acquired over the years.

As a World Trade Center survivor, I experienced firsthand the difficulty associated with overcoming unknown tragedies and traumatic experiences. When we are able-bodied, we work hard to provide a quality standard of living. However, when faced with tragedy, most of us do not have a holistic, comprehensive plan put in place to deal with what if scenarios and ensure our families are well provided for.

The Quiet Shift was written as a resource to help families address quality care and the financial costs associated with aging.

How did you feel when you found out you received a Book Excellence Award?

I was elated! It is an honor to be recognized for my work and I am eternally grateful for this acknowledgment as it will help increase my visibility as a subject matter expert in comprehensive financial planning with a focus on legacy planning.

How did your background and experience influence your writing?

In 1991 when I first started my career, my focus was on wealth accumulation. The more I began to learn about money, the more I would attribute success to elderly couples who owned a home, vacationed regularly, drove nice cars, and appeared to be generous in their giving. 

What I noticed was that more often than not, the couple would pass away and leave their property to their children, only to have it be lost or confiscated by the bank. This alarming trend was devastating because I understood that the greatest asset in a family structure was not being passed from generation to generation.

It was at that time that I began to focus on comprehensive financial planning, which included wealth accumulation and protection. I understood, as a financial planner, proper legacy planning was not being implemented.

However, the issue became a reality when my own mother was diagnosed with stage 4 pancreatic cancer, and she deteriorated quite rapidly. My experience dealing with her end-of-life care resonated so profoundly that I wanted to prepare families for the unknown nuances that are associated with aging parents in the family and the impact it has both emotionally and economically.

My commitment to legacy planning, background and my expertise has allowed me to address the intersection between caregiving, its impact on the next generation, and how it affects everyone financially.

What is one message you would like readers to remember?

My goal in writing The Quiet Shift is to help families address a difficult, extremely complicated, yet necessary conversation that must be had within a family dynamic.

The elderly population must be more transparent about their health and financial status so that medical needs and financial matters can be addressed without harmfully affecting the family.

Long term care can impact three generations within a family dynamic. If a family does not want to be depleted financially, and wants to preserve healthy family relationships, addressing how aging parents desire to be cared for during their senior years is essential.

If I could leave readers with one message, it would be to talk to the people you rely on to let them know how you desire care and what resources you have allotted to meet those needs so you can manage your resources effectively.

Purchasing the Book

The Quiet Shift is available for sale on Amazon. Readers are encouraged to purchase their copy today: https://www.amazon.com/Quiet-Shift-Navigating-Emotional-Economic/dp/B0BS8VK6PJ  

To connect with Dr. Nicole and learn more about her financial planning services, visit: https://www.harvestwealthfinancialusa.com. You can also find her on social media on Facebook, Instagram, and LinkedIn.

Media Contact
Company Name: Author News Network
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: authornewsnetwork.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Quiet Shift by Dr. Nicole B. Simpson and Sharon Stanford Recognized as a Finalist in International Book Contest

Glioblastoma Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | InovioPharma, Pfizer, Roche, ACADIA Pharma, BioNTech, Oncotelic

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Glioblastoma pipeline constitutes 195+ key companies continuously working towards developing 210+ Glioblastoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Glioblastoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Glioblastoma Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Glioblastoma Market.

 

Some of the key takeaways from the Glioblastoma Pipeline Report: 

  • Companies across the globe are diligently working toward developing novel Glioblastoma treatment therapies with a considerable amount of success over the years. 
  • Glioblastoma companies working in the treatment market are J INTS BIO, Curtana Pharmaceuticals, Prelude Therapeutics, OX2 Therapeutics, Polaris Group, Crimson Biopharm, CNS Pharmaceuticals, MimiVax, Berg, LLC, Ascletis, Denovo Biopharma, Celgene Corporation, and others, are developing therapies for the Glioblastoma treatment 
  • Emerging Glioblastoma therapies in the different phases of clinical trials are- JIN 001, CT 179, PRT3645, CD200AR L, ADI-PEG 20, CM93, Berubicin, SurVaxM, BPM31510, ASC40, Enzastaurin, Marizomib, and others are expected to have a significant impact on the Glioblastoma market in the coming years.   
  • In November 2023, The collaboration between the Global Coalition for Adaptive Research (GCAR) and the Cure Brain Cancer Foundation (CBCF) has led to the initiation of the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) trial in Australia.
  • In June 2023, Chimeric Therapeutics initiated a Phase 1B clinical study targeting individuals with recurrent and/or progressive glioblastoma multiforme (GBM). The trial aims to evaluate the safety and effectiveness of CHM 1101, their pioneering CLTX CAR T cell therapy.
  • In August 2022, Northwest Biotherapeutics obtained endorsement from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for its Pediatric Investigation Plan (PIP). Securing PIP development, regulatory assessment, and approval is essential before seeking authorization for new medications, like DCVax-L, targeting adult patients.
  • Among the up-and-coming treatments for glioblastoma, Trabedersen is currently advancing through Phase III clinical development, while Selinexor is undergoing Phase II trials.
  • Among the early-stage pipeline treatments for glioblastoma, AZD1390 is currently in Phase I clinical trials.

 

Glioblastoma Overview

Glioblastoma, also known as glioblastoma multiforme (GBM), is a type of malignant brain tumor that arises from astrocytes, a type of supportive cells in the brain. It is the most aggressive and common form of primary brain cancer in adults. Glioblastomas are highly infiltrative tumors, meaning they spread rapidly and invade surrounding brain tissue, making complete surgical removal difficult.

 

Get a Free Sample PDF Report to know more about Glioblastoma Pipeline Therapeutic Assessment- 

https://www.delveinsight.com/report-store/glioblastoma-pipeline-insight

 

Emerging Glioblastoma Drugs Under Different Phases of Clinical Development Include:

  • JIN 001: J INTS BIO
  • CT 179: Curtana Pharmaceuticals
  • PRT3645: Prelude Therapeutics
  • CD200AR L: OX2 Therapeutics
  • ADI-PEG 20: Polaris Group
  • CM93: Crimson Biopharm
  • Berubicin: CNS Pharmaceuticals
  • SurVaxM: MimiVax
  • BPM31510: Berg, LLC
  • ASC40: Ascletis
  • Enzastaurin: Denovo Biopharma
  • Marizomib: Celgene Corporation

 

Glioblastoma Route of Administration

Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

 

Glioblastoma Molecule Type

Glioblastoma Products have been categorized under various Molecule types, such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Glioblastoma Pipeline Therapeutics Assessment

  • Glioblastoma Assessment by Product Type
  • Glioblastoma By Stage and Product Type
  • Glioblastoma Assessment by Route of Administration
  • Glioblastoma By Stage and Route of Administration
  • Glioblastoma Assessment by Molecule Type
  • Glioblastoma by Stage and Molecule Type

 

DelveInsight’s Glioblastoma Report covers around 210+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Glioblastoma product details are provided in the report. Download the Glioblastoma pipeline report to learn more about the emerging Glioblastoma therapies

 

Some of the key companies in the Glioblastoma Therapeutics Market include:

Key companies developing therapies for Glioblastoma are – Array Biopharma, AstraZeneca, Doule bond Pharmaceuticals, Philogen, Immatics N.V, BioNTech, InovioPharma, Noxxon Pharma, Celgene Corporation, Karyo Pharma, Neugate Theranostics, Novartis, Orphelia Pharma, Merck, Acerta Pharma, Genenta Science, CNS Pharmaceutical, Pfizer, Roche, Oncotelic Therapeutics, Autotelic Therapeutics, ACADIA Pharmaceuticals, Mayo Clinic, Cytogel, Xgene Pharmaceutical, Ascletis, 3-V Biosciences, Yumanity Therapeutics, and others.

 

Glioblastoma Pipeline Analysis:

The Glioblastoma pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Glioblastoma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Glioblastoma Treatment.
  • Glioblastoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Glioblastoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Glioblastoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Glioblastoma drugs and therapies

 

Glioblastoma Pipeline Market Drivers

  • Rising incidence of Glioblastoma multiforme, improving Healthcare Infrastructure, demand for New and Effective Drugs are some of the important factors that are fueling the Glioblastoma Market.

 

Glioblastoma Pipeline Market Barriers

  • However, aggressive nature of GBM and the complexity of targeting the central nervous system, the current standard of care for patients with newly diagnosed glioblastoma has limited effectiveness and a second line has not been established and other factors are creating obstacles in the Glioblastoma Market growth.

 

Scope of Glioblastoma Pipeline Drug Insight    

  • Coverage: Global
  • Key Glioblastoma Companies: J INTS BIO, Curtana Pharmaceuticals, Prelude Therapeutics, OX2 Therapeutics, Polaris Group, Crimson Biopharm, CNS Pharmaceuticals, MimiVax, Berg, LLC, Ascletis, Denovo Biopharma, Celgene Corporation, and others
  • Key Glioblastoma Therapies: JIN 001, CT 179, PRT3645, CD200AR L, ADI-PEG 20, CM93, Berubicin, SurVaxM, BPM31510, ASC40, Enzastaurin, Marizomib, and others
  • Glioblastoma Therapeutic Assessment: Glioblastoma current marketed and Glioblastoma emerging therapies
  • Glioblastoma Market Dynamics: Glioblastoma market drivers and Glioblastoma market barriers 

 

Request for Sample PDF Report for Glioblastoma Pipeline Assessment and clinical trials

 

Table of Contents

1. Glioblastoma Report Introduction

2. Glioblastoma Executive Summary

3. Glioblastoma Overview

4. Glioblastoma- Analytical Perspective In-depth Commercial Assessment

5. Glioblastoma Pipeline Therapeutics

6. Glioblastoma Late Stage Products (Phase II/III)

7. Glioblastoma Mid Stage Products (Phase II)

8. Glioblastoma Early Stage Products (Phase I)

9. Glioblastoma Preclinical Stage Products

10. Glioblastoma Therapeutics Assessment

11. Glioblastoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Glioblastoma Key Companies

14. Glioblastoma Key Products

15. Glioblastoma Unmet Needs

16 . Glioblastoma Market Drivers and Barriers

17. Glioblastoma Future Perspectives and Conclusion

18. Glioblastoma Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Glioblastoma Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | InovioPharma, Pfizer, Roche, ACADIA Pharma, BioNTech, Oncotelic

STOCKROOM Launches Diverse and Unique Furniture Pieces Crafted by Skilled Artisans to Bring Customers’ Vision of a Perfect Living Space to Life

STOCKROOM supplies the best quality and stylish furniture made with the finest materials for all home and office furnishing needs to make the dream living space come true.

STOCKROOM is not just a regular furniture shop. It is a one-stop destination for all customers’ home and office furnishing needs. With an extensive collection of carefully curated pieces, customers can find everything from sofas and tables to lighting fixtures and decor items. The website offers high-quality products at affordable prices, making it possible for anyone to create their dream living space without breaking the bank. The shop also takes pride in its excellent customer service, with a team of knowledgeable and friendly representatives ready to assist with any inquiries or concerns. Whether one is looking for a specific furniture piece or needs help with interior or exterior decorating, this shop has got them covered. They can shop with confidence knowing that they are getting top-notch products and service from a trusted and reputable brand. Visit the shop today and create that perfect living space with their furniture. 

STOCKROOM

The Dining Chair Hong Kong available at STOCKROOM is a perfect example of the shop’s commitment to quality and affordability. Made from high-quality materials, this chair offers both comfort and style. It comes in various designs and colors to suit different preferences and interior styles. Customers can choose from classic wooden chairs to modern acrylic ones, all at competitive prices. The shop also offers dining tables to match with the chairs, creating a cohesive and stylish dining set. Additionally, the chairs are designed with durability in mind, ensuring that they will last for years to come.

The Bar Stool Hong Kong is another highlight of the shop. These stools are not only stylish and modern, but also functional and comfortable. With options for adjustable heights and swivel capabilities, these stools are perfect for both home bars and commercial spaces. Customers can choose from a wide range of materials such as leather, metal, and wood to fit their specific design aesthetic. And just like all the other products at this shop, these bar stools are offered at reasonable prices without compromising on quality. 

The Coffee table Hong Kong selection at STOCKROOM is also worth mentioning. These tables are not just for holding a cup of coffee but also serve as a statement piece in any living room. From sleek and minimalistic designs to unique and eye-catching ones, the shop offers something for every taste. Customers can choose from different shapes and sizes to fit their space perfectly. Some tables even come with storage options, making them a functional addition to any living room. And just like all the other furniture at this shop, these tables are made from high-quality materials and offered at affordable prices.

About STOCKROOM

STOCKROOM has quickly become a go-to destination for stylish and affordable furniture. The shop is committed to providing customers with high-quality products that are not only aesthetically pleasing but also functional and durable. With a focus on customer satisfaction, the shop has gained a loyal following of satisfied customers who continue to trust and support the brand.

Media Contact
Company Name: STOCKROOM
Contact Person: Jojoba
Email: Send Email
Phone: +852 2817 0999
Country: HongKong
Website: http://www.stockroom.com.hk/

Ridgway, CO Realtor Empowers Clients with Choice: Ninah Hunter Advocates for Informed Service Provider Selections

Ridgway, CO – In the picturesque town of Ridgway, Ninah Hunter has emerged as a leading voice for client empowerment in the real estate industry. With a firm belief in the importance of informed decision-making, Hunter is revolutionizing the way clients choose service providers during the home buying and selling process.

Hunter’s approach is refreshingly client-centric. She provides her clients with a curated list of service providers, including lenders and home inspectors, with whom she has had positive experiences. “I believe in equipping my clients with the resources they need to make the best decisions for their situation,” says Hunter. This method ensures that her clients are working with reputable professionals who are not only capable of getting the job done but also resonate with them on a personal level.

By including websites and contact information for each recommended service provider, Hunter encourages clients to conduct their own research, fostering a sense of confidence and control over their real estate journey. This practice sets her apart as a real estate agent in Ridgway, CO, dedicated to transparency and client satisfaction.

Hunter also emphasizes the value of the client-agent relationship, advising potential clients to thoroughly interview their chosen Realtor in Ridgway, CO. “It’s essential that clients feel comfortable with their agent, ensuring a partnership that is both effective and enjoyable,” Hunter adds. Her openness to this process underscores her commitment to service excellence and alignment with client needs.

For those navigating the complexities of real estate transactions in Ridgway, Ninah Hunter’s approach offers a breath of fresh air. Her advocacy for informed service provider selections and her dedication to client empowerment exemplify the qualities of a trusted Ridgway, CO Realtor.

Individuals interested in buying or selling property in Ridgway are encouraged to reach out to Ninah Hunter for a real estate experience that prioritizes choice, transparency, and informed decision-making. Visit https://www.HunterRealtyCO.com to learn more about how Hunter can assist you in finding your special spot in Ridgway.

“Empowering my clients with knowledge and choice is at the heart of everything I do,” says Hunter, inviting you to discover the difference of working with an agent who truly puts your needs first.

Media Contact
Company Name: Hunter Realty – Ninah Hunter | Real Estate Agent in Ridgway CO
Contact Person: Media Relations
Email: Send Email
Phone: +1 970-318-0086
Address:485 N Cora St
City: Ridgway
State: Colorado 81432
Country: United States
Website: https://www.hunterrealtyco.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ridgway, CO Realtor Empowers Clients with Choice: Ninah Hunter Advocates for Informed Service Provider Selections

Top Real Estate Agent in Greenbrae, CA, Recognized as Best Agent in the Area, Continues to Lead the Market

Greenbrae, CA – Jenn Pfeiffer, a well-known real estate agent in Greenbrae, CA, has once again set the benchmark for excellence in the real estate industry. With a career that spans nearly a quarter of a century, Pfeiffer’s unparalleled expertise and dedication to her clients have solidified her reputation as the leading Realtor in the area.

“Being recognized as one of the best agents in the area is not just an honor; it’s a reminder of the commitment I’ve made to serve my clients with the highest level of integrity and professionalism,” Pfeiffer remarks. This recognition is a testament to her strategic approach, innovative marketing, and deep understanding of the nuanced Greenbrae and San Francisco markets, which have consistently placed her among the top Realtors in Greenbrae, CA.

Pfeiffer’s success is built on a foundation of trust, knowledge, and an unwavering focus on achieving the best outcomes for her clients. “My philosophy is simple: listen to the clients, understand their needs, and execute a plan that exceeds their expectations,” she explains. This client-first approach has been pivotal in her recognition as a real estate selling agent in Greenbrae, CA, renowned for her ability to navigate the complexities of the real estate market while maintaining a personalized touch.

In a recent acknowledgment of excellence, Jenn Pfeiffer got an honorable mention as Best Realtor for Marin County by The Marin Independent’s Readers Choice Awards. This recognition not only honors her outstanding achievements but also reinforces her status as a premier agent, underscoring her strong position in the local real estate market.

Throughout her dynamic career, Pfeiffer has demonstrated an exceptional ability to adapt to market changes, leverage cutting-edge technology for marketing, and maintain a network of industry connections that benefit her clients in every transaction. “Every home has a story, and my role is to tell that story in a way that resonates with buyers and sellers alike,” Pfeiffer adds, emphasizing her commitment to excellence.

For those seeking to buy or sell in Greenbrae, CA, Jenn Pfeiffer offers an unmatched level of service and expertise. Visit http://www.jennpfeiffer.com/ to learn how partnering with an award-winning Realtor can elevate your real estate experience.

Media Contact
Company Name: Jenn Pfeiffer, Realtor | Real Estate Agent in Greenbrae, CA
Contact Person: Jenn Pfeiffer
Email: Send Email
Phone: +1 415 302 3198
Address:100 Drakes Landing Rd #125
City: Greenbrae
State: California 94904
Country: United States
Website: http://www.jennpfeiffer.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Top Real Estate Agent in Greenbrae, CA, Recognized as Best Agent in the Area, Continues to Lead the Market

Durham, NC, Real Estate Agent Steed Rollins Shares The Advantages Of Utilizing Extensive Local Expertise for Client Advantage

Steed Rollins, a respected real estate agent in Durham, NC, highlights the benefits of leveraging his in-depth local knowledge to assist clients in the real estate market. His lifelong residency and comprehensive understanding of Durham’s real estate dynamics offer clients a distinct advantage.

“Having been a part of Durham’s community my entire life, I bring a unique perspective to each transaction,” Rollins notes. As a top Realtor agent in Durham, NC, his insights into neighborhood trends, property values, and market movements are invaluable to both buyers and sellers.

Rollins’ approach is tailored to each client’s needs. “My aim is to align my services with my clients’ goals, whether they’re first-time buyers, seasoned investors, or looking to sell their property,” he explains. His expertise as a real estate buying agent is evident in his ability to match buyers with homes that perfectly fit their requirements.

As a real estate selling agent in Durham, NC, Rollins excels in marketing properties effectively. “My goal is to showcase each home’s unique features, ensuring it reaches the right audience and achieves the best possible price,” he says.

Rollins invites those interested in buying or selling in the area to experience his high-level service. “Let me guide you through your real estate journey with the knowledge and care you deserve,” he concludes.

For those looking to buy or sell property in Durham, NC, Steed Rollins is a name synonymous with reliability, expertise, and personalized service. For more information, visit Steed Rollins’ website and discover the advantages of working with a leading Realtor in Durham, NC. Learn more at the website. Visit http://steedrollins.com/.

Media Contact
Company Name: Steed Rollins Realtor
Contact Person: Steed Rollins
Email: Send Email
Phone: 919-306-9767
Country: United States
Website: http://steedrollins.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Durham, NC, Real Estate Agent Steed Rollins Shares The Advantages Of Utilizing Extensive Local Expertise for Client Advantage

MVRS Weddings: Transforming the Wedding Industry with Innovative Technology

The art of planning a wedding has evolved significantly over the years. From the days of handwritten invitations and physical photo albums to today’s digital age, where everything from vendor selection to guest management can be done online, the wedding planning process has undergone a remarkable transformation.

In the past, planning a wedding was a time-consuming and often stressful task. Couples would spend hours visiting vendors, flipping through catalogs, and managing endless lists of tasks. Today, thanks to the advent of technology, planning a wedding has become easier, more efficient, and more enjoyable than ever before.

Modern couples now have access to a plethora of tools and resources that make planning their special day a breeze. As we move further into the digital age, the wedding industry is poised for even more innovation. With technologies like virtual reality and blockchain on the horizon, the future of wedding planning promises to be even more exciting and transformative. 

As we look to the future, one of the most exciting developments in the world of weddings is the emergence of the metaverse. The metaverse, a collective virtual shared space, is poised to revolutionize the way we experience weddings, offering a new level of immersion and interactivity that was previously unimaginable.

MVRS WEDDINGS is more than just a wedding planning platform; it’s a revolution in the bridal world. With cutting-edge technology and an innovative vision, MVRS WEDDINGS is poised to fundamentally change the way couples plan and experience their special day.

Imagine an intuitive tool that guides you step by step through the entire wedding planning process. With an easy-to-use interface and smart features, MVRS WEDDINGS simplifies every aspect of the process, allowing you to enjoy the journey to your perfect day without stress or complications.

But MVRS WEDDINGS goes beyond basic wedding planning. With its focus on innovation, the platform offers unique features that elevate the bridal experience to new heights. MVRS WEDDINGS offers you a completely new and exciting experience.

Best of all, MVRS WEDDINGS is designed to adapt to your individual needs and desires. Whether you’re looking for an intimate and romantic event or an extravagant and luxurious celebration, MVRS WEDDINGS gives you the tools and flexibility to create the wedding of your dreams.

MVRS WEDDINGS is set to revolutionize the wedding industry by integrating cutting-edge virtual reality systems, offering an unparalleled and immersive wedding planning experience.

The MVRS WEDDINGS platform will be launching soon and will be available to users worldwide. Ready to embark on a new era of wedding planning? Join our waitlist now and be among the first to experience the future of weddings with MVRS WEDDINGS. Don’t miss out on the opportunity to revolutionize the way you plan and experience your special day. Register today and be prepared to witness the wedding industry evolution firsthand.

For more information and to stay updated on the latest developments, visit our official website.

https://mvrsweddings.com/

Instagram: @mvrsweddings

Media Contact
Company Name: MVRS Weddings
Email: Send Email
Country: Mexico
Website: https://mvrsweddings.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: MVRS Weddings: Transforming the Wedding Industry with Innovative Technology

I BUY LA Expands Into All California Markets Enabling Homeowners To Sell Their Homes Fast and Efficiently

I BUY LA Expands Into All California Markets Enabling Homeowners To Sell Their Homes Fast and Efficiently
I BUY LA announces an expansion into all California markets. I BUY LA has provided access to quick and easy home sales throughout neighboring markets and due to customer demand expanded quickly into all major markets in the region. Furthermore, I BUY LA has introduced a helpful service that allows homeowners to sell their properties for cash before relocating. Homeowners in the area who want cash for their home can receive a free offer.

California – I BUY LA, headed by Yosef Adde, buys houses in all California counties. The company that buys houses gives cash for properties anywhere in California and are committed real estate investors in the region. I BUY LA guiding principles is to stay small and lightweight to afford giving the homeowner the highest possible cash offer for their house. Therefore, the company does everything from acquiring properties, overseeing renovations, and marketing. They keep their margins modest and work with local California contractors to keep repair costs low. I BUY LA also enjoys assisting homeowners in escaping less-than-ideal situations and undertaking renovation projects of any size.

Instead of paying a commission and waiting months to sell a home, I BUY LA makes it fast and easy by making repairs, cleaning, and buying in cash so there’s no financing. You don’t have to deal with locating a real estate agent, or dealing with open houses and showings. They take up the home seller’s position and, in so doing, make life easy for them. I BUY LA buys houses in any condition for cash in California, which means that sellers can earn cash for their house while saving tens of thousands of dollars and a significant amount of time.

Since 2019, I BUY LA has been making cash offers to homeowners who want to sell a house, townhome, condo, or apartment that they no longer want. Sellers will receive cash for their homes regardless of their situation from having trouble paying their mortgage, trying to prevent foreclosure, or needing some extra income, to any other reason, such as not wanting to deal with realtors. I BUY LA takes pride in providing property owners in California and the surrounding areas with direct selling benefits. The home buyers at I BUY LA are people-oriented, and they take satisfaction in listening to the sellers’ inquiries while properly explaining the home sale process to them.

Property owners in and around California and surrounding areas can rest easy knowing that they will have access to a faster home sale process, one that can be completed in 7 days or on the seller’s timeline. They will also be saving money on commissions, agent fees, closing costs, and more with the help of I BUY LA.

To learn more about I BUY LA, Contact them via phone at 310-363-7361. For more information, visit their website.

Media Contact
Company Name: I BUY LA
Contact Person: Yosef Adde
Email: Send Email
Phone: 310-363-7361
Address:225 Pacific Coast Hwy Suite C
City: Hermosa Beach
State: California 90254
Country: United States
Website: www.ibuy.la/

Dallas Fort Worth Business Turnaround Consultants Offer Enhanced Digital Marketing Services Including SEO And New Web3 Marketing Methods

Dallas Fort Worth Business Turnaround Consultants Offer Enhanced Digital Marketing Services Including SEO And New Web3 Marketing Methods

BRProfits Logo
DFW business turnaround consulting firm, BRProfits, adds SEO and additional local online marketing services including NFTs, web3, virtual real estate and more.

Today BRProfits, a Dallas Fort Worth Texas business turnaround and consulting firm located in Addison TX, announced that it has added enhanced online marketing services for its local business clients. The services include traditional SEO, SEM, online Maps, and video marketing offerings; and the company has included new technologies such as search engine marketing using web3 platforms such as virtual lands (digital real estate), NFTs, POAPs, and metaverse platforms.

Mansour Khayal, founder of BRProfits, said, “While helping a wide range of businesses in the DFW and North Texas region with their turnaround plans, almost every business owner and I discovered a significant lack of inbound traffic to their websites and other online entities which favorably mention the company. While they engage in social media efforts to varying degrees, almost all of these businesses felt that the lack of qualified prospective customers/clients coming from inbound traffic was a major reason for some of the obstacles that these businesses faced.”

He continued, “The business owners were confused and overwhelmed with keeping up with the search engine algorithm changes as well as advances in new technologies such as web3 platforms like metaverse, NFTs, virtual real estate, and more. Furthermore, they felt inundated by the constant barrage of SEO-related email and phone call solicitations from parties claiming to help their search engine rankings; but those businesses had no idea of the business owners’ actual needs nor industry-specific needs nor understanding the dynamics of the Texas market. We believe that by being local, understanding the true needs of these business owners, and having proof of success using a blend of traditional and new online marketing methods will help BRProfits give our clients higher chances of getting a true return-on-investment in their inbound marketing efforts.”

According to the firm’s website, it has helped clients across a wide range of industries in the Dallas Fort Worth and North Texas market. These include medical and healthcare, legal, financial services, automotive, construction, restaurants and more. Khayal indicated that additional team members being brought in to grow BRProfits’ offerings have successful search engine ranking proof (as of March 2024) in Dallas Fort Worth niches such as heating and cooling, video production, pest control, e-commerce products, education, home building, entertainment, professional sports, and other industries.

Parties interested in BRProfits’ services are welcome to contact the company through its phone number, website, LinkedIn page or YouTube channel. Media interested in topics related to changes in the search engines, new local online marketing methods, and ways in which local business owners can adapt new technologies such as NFTs and virtual lands (digital real estate) are welcome to contact the company in the same manners.

Media Contact
Company Name: BRProfits
Contact Person: Mansour Khayal
Email: Send Email
Phone: 972-701-9999
Address:15620 Quorum Dr
City: Addison
State: Texas
Country: United States
Website: www.brprofits.com/